Skip to main content
SpringerLink
Log in

Adenosine Receptors: The Status of the Art

  • Chapter
  • First Online:
The Adenosine Receptors

Part of the book series: The Receptors ((REC,volume 34))

Abstract

Adenosine is an ubiquitous molecule which is involved in the regulation of the function of every tissue and organ. This nucleoside mediates its effects through activation of a family of four G-protein-coupled adenosine receptors, namely, A1, A2A, A2B, and A3. Adenosine plays a significant role in the protection against cellular damage in the regions with high metabolism and prevents the subsequent dysfunction of the affected organs. Its levels rise during conditions concerning increased metabolic demand and/or lack of oxygen occurring in several pathological states like ischemia, stress, seizures, pain, diabetes, inflammation, cancer, and trauma, where it may behave like a guardian angel against cellular damage or may show its bad side in conditions deriving from its long-lasting increases responsible for chronic inflammation, fibrosis, and organ damage. The aim of this chapter is to offer an overview on the status of the art of the current drugs, agonists and antagonists, in clinical development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Baraldi PG, Tabrizi MA, Gessi S, Borea PA (2008) Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 108:238–263

    Article  CAS  PubMed  Google Scholar 

  • Bar-Yehuda S, Stemmer SM, Madi L et al (2008) The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 33:287–295

    PubMed  CAS  Google Scholar 

  • Borea PA, Varani K, Vincenzi F et al (2015) The A3 adenosine receptor: history and perspectives. Pharmacol Rev 67:74–102

    Article  CAS  PubMed  Google Scholar 

  • Borea PA, Gessi S, Merighi S, Varani K (2016) Adenosine as a multi-Signalling Guardian angel in human diseases: when, where and how does it exert its protective effects? Trends Pharmacol Sci 37:419–434

    Article  CAS  PubMed  Google Scholar 

  • Borea PA, Gessi S, Merighi S et al (2017) Pathological overproduction: the bad side of adenosine. Br J Pharmacol 174:1945–1960

    Article  CAS  PubMed  Google Scholar 

  • Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO et al (2010) Characterization of the A2AR–D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem Biophys Res Commun 402:801–807

    Article  CAS  PubMed  Google Scholar 

  • Canals M, Marcellino D, Fanelli F et al (2003) Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278:46741–46749

    Article  CAS  PubMed  Google Scholar 

  • Chen JF, Eltzschig HK, Fredholm BB (2013) Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov 12:265–286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • David M, Akerman L, Ziv M et al (2012) Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 26:361–367

    Article  CAS  PubMed  Google Scholar 

  • David M, Gospodinov DK, Gheorghe N et al (2016) Treatment of plaque-type psoriasis with oral CF101: data from a phase II/III multicenter, randomized, controlled trial. J Drugs Dermatol 15:931–938

    PubMed  CAS  Google Scholar 

  • Ferre S, von Euler G, Johansson B et al (1991) Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci U S A 88:7238–7241

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fishman P, Cohen S (2016) The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol 35:2359–2362

    Article  PubMed  Google Scholar 

  • Fishman P, Bar-Yehuda S, Madi L, Cohn I (2002) A3 adenosine receptor as a target for cancer therapy. Anti-Cancer Drugs 13:437–443

    Article  CAS  PubMed  Google Scholar 

  • Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA (2012) Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today 17:359–366

    Article  CAS  PubMed  Google Scholar 

  • Fuxe K, Agnati LF, Jacobsen K et al (2003) Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson’s disease. Neurology 61:S19–S23

    Article  CAS  PubMed  Google Scholar 

  • Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO (2015) Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin Ther Targets 19:377–398

    Article  CAS  PubMed  Google Scholar 

  • Gao Z-G, Jacobson KA (2017) Purinergic signaling in mast cell degranulation and asthma. Front Pharmacol 8:947

    Article  PubMed  PubMed Central  Google Scholar 

  • Gessi S, Cattabriga E, Avitabile A et al (2004) Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 10:5895–5901

    Article  CAS  PubMed  Google Scholar 

  • Gessi S, Merighi S, Varani K et al (2008) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117:123–140

    Google Scholar 

  • Gessi S, Merighi S, Fazzi D et al (2011) Adenosine receptor targeting in health and disease. Expert Opin Investig Drugs 20:1591–1609

    Article  CAS  PubMed  Google Scholar 

  • Greene SJ, Sabbah HN, Butler J et al (2016) Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev 21:95–102

    Article  CAS  PubMed  Google Scholar 

  • Kirsch GE, Codina J, Birnbaumer L, Brown AM (1990) Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 259:H820–H826

    Article  CAS  Google Scholar 

  • Lukashev D, Sitkovsky M, Ohta A (2007) From Hellstrom paradox–to anti-adenosinergic cancer immunotherapy. Purinergic Signal 3:129–134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Madi L, Ochaion A, Rath-Wolfson L et al (2004) The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10:4472–4479

    Article  CAS  PubMed  Google Scholar 

  • Meibom D, Albrecht-Küpper B, Diedrichs N et al (2017) Neladenoson Bialanate hydrochloride: a prodrug of a partial adenosine a 1 receptor agonist for the chronic treatment of heart diseases. ChemMedChem 12:728–737

    Article  CAS  PubMed  Google Scholar 

  • Merighi S, Mirandola P, Varani K et al (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100:31–48

    Article  CAS  PubMed  Google Scholar 

  • Navarro G, Borroto-Escuela DO, Fuxe K, Franco R (2016) Purinergic signaling in Parkinson’s disease. Relevance for treatment. Neuropharmacology 104:161–168

    Article  CAS  PubMed  Google Scholar 

  • Newby AC (1984) Adenosine and the concept of “retaliatory metabolites”. Trends Biochem Sci 9:42–44

    Article  CAS  Google Scholar 

  • Ochaion A, Bar-Yehuda S, Cohen S et al (2008) The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 76:482–494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ochaion A, Bar-Yehuda S, Cohen S et al (2009) The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cell Immunol 258:115–122

    Article  CAS  PubMed  Google Scholar 

  • Peleli M, Fredholm BB, Sobrevia L, Carlström M (2017) Pharmacological targeting of adenosine receptor signaling. Mol Asp Med 55:4–8

    Article  CAS  Google Scholar 

  • Preti D, Baraldi PG, Moorman AR et al (2015) History and perspectives of a 2A adenosine receptor antagonists as potential therapeutic agents. Med Res Rev 35:790–848

    Article  CAS  PubMed  Google Scholar 

  • Stemmer SM, Benjaminov O, Medalia G et al (2013) CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist 18:25–26

    Article  PubMed  PubMed Central  Google Scholar 

  • van Calker D, Müller M, Hamprecht B (1979) Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 33:999–1005

    Article  PubMed  Google Scholar 

  • Varani K, Caramori G, Vincenzi F et al (2006) Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173:398–406

    Article  CAS  PubMed  Google Scholar 

  • Varani K, Vincenzi F, Merighi S et al (2017) Biochemical and pharmacological role of A1 adenosine receptors and their modulation as novel therapeutic strategy. Adv Exp Med Biol 1051:193–232

    Article  PubMed  Google Scholar 

  • Yuan K, Cao C, Han JH et al (2005) Adenosine-stimulated atrial natriuretic peptide release through A1 receptor subtype. Hypertension 46:1381–1387

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    Stefania Gessi, Stefania Merighi & Katia Varani

Authors
  1. Stefania Gessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefania Merighi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katia Varani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefania Merighi .

Editor information

Editors and Affiliations

  1. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    Pier Andrea Borea

  2. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    Katia Varani

  3. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    Stefania Gessi

  4. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    Stefania Merighi

  5. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    Fabrizio Vincenzi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gessi, S., Merighi, S., Varani, K. (2018). Adenosine Receptors: The Status of the Art. In: Borea, P., Varani, K., Gessi, S., Merighi, S., Vincenzi, F. (eds) The Adenosine Receptors. The Receptors, vol 34. Humana Press, Cham. https://doi.org/10.1007/978-3-319-90808-3_1

Download citation

Publish with us

Policies and ethics

Search

Navigation